Inclisiran: A Novel Agent for Lowering Apolipoprotein B-Containing Lipoproteins.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of cardiovascular pharmacology"
DOI: 10.1097/fjc.0000000000001053
Abstract: ABSTRACT Hypercholesterolemia is a leading cause of cardiovascular morbidity and mortality. Accordingly, efforts to lower apolipoprotein B-containing lipoproteins in plasma are the centerpiece of strategies for cardiovascular prevention and treatment in primary and secondary management.… read more here.
Keywords: novel agent; lowering apolipoprotein; containing lipoproteins; inclisiran novel ... See more keywords
Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Preventive Cardiology"
DOI: 10.1177/2047487319871733
Abstract: Aims The effect of therapeutic lowering of apolipoprotein B (apoB) on mortality and major adverse cardiovascular events is uncertain. It is also unclear whether these potential effects vary by different lipid-lowering strategies. Methods A total… read more here.
Keywords: association lowering; mortality; meta; lipid lowering ... See more keywords